LaRed Home

LaRed

NTZ-SARI

A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Nitazoxanide Versus Placebo in Addition to Standard Care for the Treatment of Hospitalized Subjects with Severe Acute Respiratory Illness

by

Respiratory viral infections are major causes of severe acute respiratory illness (SARI) and can lead to severe outcomes including hospitalization. This study evaluated the safety, effectiveness, and tolerability of nitazoxanide (NTZ), in combination with standard of care, in treating SARI in people who were hospitalized. This study started on February 2014 and was completed on January 2018 with an enrollment of 260 participants. It was concluded that treatment with nitazoxanide did not reduce the duration of hospital stay in severe influenza-like illness. Further analyses based on age and evaluations by virus did not reveal any subgroups that appeared to benefit from nitazoxanide.